about
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisNon-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisAcetyl-L-carnitine for patients with hepatic encephalopathyProbiotics for patients with hepatic encephalopathyProbiotics for hepatic encephalopathyNaloxone for hepatic encephalopathyNutritional assessment in cirrhotic patients with hepatic encephalopathyManagement of overt hepatic encephalopathyAntibiotics for the treatment of hepatic encephalopathyComplications of end-stage liver diseaseEvaluation of the impact of rehospitalization in the management of hepatic encephalopathySafety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathyManagement of Hepatic Encephalopathy: A PrimerHyperammonemia and systemic inflammatory response syndrome predicts presence of hepatic encephalopathy in dogs with congenital portosystemic shuntsMinimal hepatic encephalopathyCirrhosis and its complications: evidence based treatment.Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.Embolization of splenorenal shunt associated to portal vein thrombosis and hepatic encephalopathyProspective Multicenter Observational Study of Overt Hepatic Encephalopathy.Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind studyMELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathyIntestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "Top-Down" approach to intestinal fibrosis in miceMinimal hepatic encephalopathy impairs quality of life.Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt CreationRiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.Bacopa monnieri Extract (CDRI-08) Modulates the NMDA Receptor Subunits and nNOS-Apoptosis Axis in Cerebellum of Hepatic Encephalopathy RatsCovert and Overt Hepatic Encephalopathy: Diagnosis and ManagementReview of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy.Update on the management of cirrhosis - focus on cost-effective preventative strategiesBiologics in Crohn's disease: searching indicators for outcome.CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosisEndoscopic evaluation of patients with inflammatory bowel disease.Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy.Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States.Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults.Specific considerations in the treatment of pediatric inflammatory bowel disease.Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes.Rifaximin in the treatment of hepatic encephalopathy.Positioning biologic agents in the treatment of Crohn's disease.
P2860
Q24185782-6F3C5443-E5EF-40F3-AF5F-CC9F13800C37Q24185895-77CA9A73-D93A-47B3-BCE6-9B91C8B28ED2Q24187553-E1A12ECE-2420-42EC-9E23-FC499441343FQ24235259-820EDB8F-E67D-474B-9E52-3148636A2E48Q24236083-72609C8C-9498-4DB3-B773-0A77DCC5F5C1Q24240885-F716D814-15AE-4235-B30B-A31E4962BABDQ26771155-7E265E40-ACDC-4CE3-BDC4-562C57A77F90Q26830789-711F615A-BEFF-4169-9716-4EF567295089Q27012878-F35668D5-D14B-4B57-B440-911645694900Q28073114-A77849A7-CC4D-4BAD-AF86-741DF309A4E3Q28085014-E1535A3D-2597-441C-97EE-016CF57957F8Q28236913-692C6ADA-A486-4331-9499-01A7F97A3BB1Q28275197-394DE7C5-53B5-4B85-9616-CB7CB7541995Q28538254-D31054B8-84C7-4855-996C-B0C4C838EC05Q33440095-DBEA2647-3910-4F40-9277-83AA1BABB86FQ33594931-F38AB433-22C8-48FC-99A4-0E25E78467FDQ33805285-6CF830FE-8CAE-4673-8D03-95A6F146C591Q34381832-929EF99A-1119-4093-B693-1EE1177F60AFQ34499231-66D36A84-69D5-4AD0-ADB4-2ECF25700794Q34509599-947BAD02-7767-4BB1-816F-AFBFA675BCFEQ34550014-50CAE355-9660-4055-8870-D1458643B59DQ34874260-A6CD6FF5-41EF-45EF-AF85-A4AD25A48E1EQ35510528-675F9530-F447-4874-BA13-A8A79EC0C4D0Q35642834-3C60BD49-50AF-456E-B26F-EC464216BAACQ35667270-AE1FB8B4-C82E-4F33-8DFD-DA5A6F41E225Q35939710-8877937D-457F-488E-B75E-46E39A02A45EQ36043633-FF18798B-1DBA-41E6-80B6-61687C21DA28Q36199772-9568D34D-001B-4374-801A-285DAF608288Q36734114-2AD19BC4-E39D-4624-828B-B70E3AF59C1BQ36784836-50F125A3-6763-4073-A799-F7A697BAFD6CQ36909385-7216C42D-AE6E-4F45-AA89-BB4D6E92F537Q37077879-4ED46D38-47D1-4D3B-B4F5-632C5ED0EE5AQ37094727-FADAD49C-B57B-46C4-BB8E-2A285429E49DQ37142443-56C5F838-78F2-4A6A-9514-FFED4471FF9AQ37204909-3066FC36-E890-404A-90F6-00EB4A59C557Q37345854-A5FD4F16-37E3-466E-8CD5-0827ECD9D7E8Q37345918-FF836171-0C31-416F-AAB0-16153A60DAF9Q37353473-68E54186-AC71-404A-A83E-9FAB938AE130Q37355818-9E126370-EF0A-4B35-906A-7FFC2B05CBA6Q37421884-0719ECDC-96E6-466B-B4B2-EEC15DA9023F
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Review article: the burden of hepatic encephalopathy.
@ast
Review article: the burden of hepatic encephalopathy.
@en
type
label
Review article: the burden of hepatic encephalopathy.
@ast
Review article: the burden of hepatic encephalopathy.
@en
prefLabel
Review article: the burden of hepatic encephalopathy.
@ast
Review article: the burden of hepatic encephalopathy.
@en
P1476
Review article: the burden of hepatic encephalopathy.
@en
P2093
Poordad FF
P2860
P356
10.1111/J.1746-6342.2006.03215.X
P407
P478
25 Suppl 1
P577
2007-02-01T00:00:00Z